Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
67 hedge funds and large institutions have $34.2M invested in Syros Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 25 reducing their positions, and 37 closing their positions.
29% less funds holding
Funds holding: 94 → 67 (-27)
32% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 25
35% less capital invested
Capital invested by funds: $53.1M → $34.2M (-$18.8M)
68% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 37
80% less call options, than puts
Call options by funds: $2K | Put options by funds: $10K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$587K |
| 2 |
AG
Artal Group
Luxembourg
|
+$468K |
| 3 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$468K |
| 4 |
Millennium Management
New York
|
+$423K |
| 5 |
E
Ergoteles
New York
|
+$252K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.72M |
| 2 |
BlackRock
New York
|
-$2.48M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.07M |
| 4 |
State Street
Boston,
Massachusetts
|
-$868K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$695K |
SYRS Hedge Fund Activity: Q2 2022 in Review
67 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2022, worth a combined $34.2M — down 35% from $53.1M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of SYRS and 12 opened new positions — a net loss of 25 holders — while 25 trimmed existing stakes and 17 added.
The largest buyer was Vanguard Group, adding an estimated $587K. The largest seller was Fidelity Investments, cutting an estimated $2.72M.
- 67 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2022, down from 94 in Q1 2022.
- Funds reported $34.2M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 35% quarter-over-quarter.
- 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 37 closed out, a net change of -25 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Vanguard Group, an estimated $587K added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Fidelity Investments, an estimated $2.72M sold.
Based on aggregated 13F filings for Q2 2022.